SQZ Biotech has a promising new way of transforming cell behavior. This technology from MIT’s storied Langer Lab is backed by a $500 Million collaboration with Roche, the biggest maker of cancer drugs, and $24 million in VC money.

Sal Daher, CFA, together with other angels, is an investor in SQZ Biotech. To learn more about investing alongside Sal and his colleagues in this type of startup please enter your email address:

Investments in Startups are Inherently Risky. Such investments should only be undertaken by financially sophisticated persons who are accredited investors as defined under US securities laws and who are capable of bearing the risks involved. Do seek independent investment advice in making your decision to invest. We do not provide investment advice.

 

LISTEN TO SAL’S INTERVIEW OF ARMON SHAREI, CEO OF SQZ BIOTECH HERE


CURRENT PODCAST EPISODE

A New Podcast EpisodE IS Released Every Wednesday. 

Brilliant Spanish postdoc, Carlos Castro-González, goes to MIT’s “Magic Wand” lab, and joins a superb international team to address an important medical problem. Leuko, their startup, now has a device and software that can tell when cancer patients are becoming immuno-compromised. Leuko’s product has the potential of saving 4,000 lives and $1.5 billion every year by cutting in half opportunistic infections associated with chemotherapy. 



FEATURED EPISODES


SUBSCRIBE

New episodes released every Wednesday. Subscribe to our podcast on iTunes to make certain you never miss an episode: